Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Amundi

Amundi grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 28.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 719,279 shares of the medical equipment provider's stock after purchasing an additional 160,765 shares during the quarter. Amundi owned approximately 0.38% of Zimmer Biomet worth $61,923,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ZBH. DV Equities LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $25,000. Tacita Capital Inc acquired a new position in Zimmer Biomet during the second quarter worth approximately $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet during the second quarter worth approximately $29,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $30,000. Finally, Gen Wealth Partners Inc acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the company's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.28% of the company's stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $92.30 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $106.88. The company has a market capitalization of $17.61 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 1.79 and a beta of 0.47. The business has a 50-day moving average of $95.42 and a 200-day moving average of $91.51.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the business posted $2.07 EPS. The company's revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet's payout ratio is presently 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research analyst reports. Weiss Ratings upgraded Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, August 4th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday, August 6th. Stifel Nicolaus boosted their price target on Zimmer Biomet from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Canaccord Genuity Group upped their price target on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a research note on Monday, August 10th. Finally, UBS Group restated a "buy" rating and issued a $120.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc NYSE: ZBH is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.